Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Upstream Bio (NASDAQ:UPB) has scheduled a conference call and webcast for September 2, 2025, at 8:00 a.m. ET to present top-line data from its Phase 2 VIBRANT trial. The study evaluates verekitug, a unique monoclonal antibody targeting TSLP receptor, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
The VIBRANT trial (NCT06164704) is a global, randomized, placebo-controlled study where participants received either 100 mg of verekitug or placebo subcutaneously every 12 weeks for 24 weeks. The trial's primary endpoint focuses on measuring changes in endoscopic nasal polyp score at Week 24.
Upstream Bio (NASDAQ:UPB) ha programmato una conference call e una webcast per il 2 settembre 2025 alle 8:00 a.m. ET per presentare i dati principali del suo trial di Fase 2 VIBRANT. Lo studio valuta verekitug, un anticorpo monoclonale distintivo che mira al recettore TSLP, in pazienti con rinosinusite cronica con polipi nasali (CRSwNP).
Il trial VIBRANT (NCT06164704) 猫 uno studio globale, randomizzato e controllato con placebo: i partecipanti hanno ricevuto 100 mg di verekitug o placebo per via sottocutanea ogni 12 settimane per 24 settimane. L'endpoint primario 猫 la variazione del punteggio endoscopico dei polipi nasali alla Settimana 24.
Upstream Bio (NASDAQ:UPB) ha programado una conferencia telef贸nica y una retransmisi贸n por web para el 2 de septiembre de 2025 a las 8:00 a.m. ET para presentar los datos principales de su ensayo de Fase 2 VIBRANT. El estudio eval煤a verekitug, un anticuerpo monoclonal 煤nico dirigido al receptor de TSLP, en pacientes con rinosinusitis cr贸nica con p贸lipos nasales (CRSwNP).
El ensayo VIBRANT (NCT06164704) es un estudio global, aleatorizado y controlado con placebo en el que los participantes recibieron 100 mg de verekitug o placebo por v铆a subcut谩nea cada 12 semanas durante 24 semanas. El criterio de valoraci贸n primario mide el cambio en la puntuaci贸n endosc贸pica de los p贸lipos nasales en la Semana 24.
Upstream Bio (NASDAQ:UPB)電� 2025雲� 9鞗� 2鞚� 氙� 霃欕秬鞁滉皠 鞓れ爠 8:00鞐� 欤检殧 瓴瓣臣毳� 氚滍憸頃橁赴 鞙勴暅 旎嵓霟办姢 旖� 氚� 鞗箘雮橂ゼ 鞓堨爼頄堨姷雼堧嫟. 鞚� 鞐瓣惮電� 毵岇劚 牍勲秬牍勲彊鞐� 霃欕皹 牍勱皶 韽措(CRSwNP) 頇橃瀽毳� 雽�靸侅溂搿� TSLP 靾橃毄觳措ゼ 響滌爜鞙茧 頃橂姅 霃呿姽頃� 雼伌搿犿暛觳� verekitug鞚� 韽夑皜頃╇媹雼�.
VIBRANT 鞛勳儊鞁滍棙 (NCT06164704)鞚� 鞝� 靹戈硠 雼り赴甏� 氍挫瀾鞙� 氚办爼 鞙勳暯 雽�臁� 鞐瓣惮搿�, 彀戈皜鞛愲摛鞚� 24欤� 霃欖晥 12欤� 臧勱博鞙茧 頂柬晿欤检偓 氚╈嫕鞙茧 verekitug 100 mg 霕愲姅 鞙勳暯鞚� 韴棳氚涭晿鞀惦媹雼�. 鞚检皑 韽夑皜電� 24欤� 彀� 雮挫嫓瓴� 牍勱皶 韽措 鞝愳垬 氤�頇旍瀰雼堧嫟.
Upstream Bio (NASDAQ:UPB) a programm茅 une conf茅rence t茅l茅phonique et un webinaire pour le 2 septembre 2025 脿 8:00 a.m. ET afin de pr茅senter les donn茅es principales de son essai de phase 2 VIBRANT. L'茅tude 茅value verekitug, un anticorps monoclonal unique ciblant le r茅cepteur TSLP, chez des patients atteints de rhinosinusite chronique avec polypes nasaux (CRSwNP).
L'essai VIBRANT (NCT06164704) est une 茅tude mondiale, randomis茅e et contr么l茅e par placebo dans laquelle les participants ont re莽u 100 mg de verekitug ou un placebo par voie sous-cutan茅e toutes les 12 semaines pendant 24 semaines. Le crit猫re d'茅valuation principal porte sur la variation du score endoscopique des polypes nasaux 脿 la semaine 24.
Upstream Bio (NASDAQ:UPB) hat f眉r den 2. September 2025 um 8:00 a.m. ET eine Telefonkonferenz und ein Webcast angesetzt, um die Topline-Daten seiner Phase-2-Studie VIBRANT vorzustellen. Die Studie untersucht verekitug, einen einzigartigen monoklonalen Antik枚rper gegen den TSLP-Rezeptor, bei Patienten mit chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP).
Die VIBRANT-Studie (NCT06164704) ist eine globale, randomisierte, placebokontrollierte Studie, in der die Teilnehmer alle 12 Wochen 眉ber 24 Wochen subkutan entweder 100 mg verekitug oder Placebo erhielten. Der prim盲re Endpunkt ist die Ver盲nderung des endoskopischen Nasenpolypen-Scores in Woche 24.
- None.
- None.
鈥� Conference Call and Webcast to be held Tuesday, September 2, 2025, at 8:00 a.m. ET 鈥�
WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line data from the Phase 2 VIBRANT trial of verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), on Tuesday, September 2, 2025.
The VIBRANT trial (NCT06164704) was a Phase 2 global, randomized, placebo-controlled, parallel group clinical trial designed to assess the efficacy and safety of verekitug in adults with CRSwNP. Participants received either 100聽mg of verekitug or placebo subcutaneously every 12 weeks for 24 weeks. The primary endpoint was change in endoscopic nasal polyp score (NPS) at Week 24.
Conference Call and Webcast
Upstream Bio鈥檚 conference call and webcast to discuss the top-line data results from the Phase 2 VIBRANT trial will begin Tuesday, September 2, 2025, at 8:00 a.m. ET. The live webcast can be accessed via this or on the Events tab on the Investors section of the Company鈥檚 website at . A replay of the webcast will be available on the website following the call.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio鈥檚 team is committed to maximizing verekitug鈥檚 unique attributes to address the substantial unmet needs for patients underserved by today鈥檚 standard of care. To learn more, please visit聽.
Investor and Media Contact: Meggan Buckwell Director, Corporate Communications and Investor Relations [email protected]
FAQ
When will Upstream Bio (UPB) report Phase 2 VIBRANT trial results?
What is the primary endpoint of Upstream Bio's Phase 2 VIBRANT trial?
How is verekitug administered in the Upstream Bio VIBRANT trial?
What makes Upstream Bio's verekitug unique in clinical development?
How can investors access Upstream Bio's VIBRANT trial results webcast?
